| Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells. | None |
| Data suggest mechanisms of carcinogenesis by heavy metals involve increased activation of signaling pathways involving EGFR, PI3K/AKT (phosphatidylinositol 3-kinase/proto-oncogene protein c-AKT), and mTOR (mechanistic target of rapamycin). [REVIEW] | None |
| Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling. | None |
| Opposing roles of the oncogene Akt isoforms in tumour progression: is there a dark side to Akt pathway inhibition?. | None |
| ARF stability control is crucial for differentiating normal versus oncogenic levels of c-Myc expression and suggests that differential effects on ULF- mediated ARF ubiquitination by c-Myc levels act as a barrier in oncogene-induced stress responses. | None |
| Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo. | None |
| Data indicate that MK-2206 at maximum tolerated doses only modest decreases in proto-oncogene c-Akt (AKT). | None |
| Data indicate that malic enzyme 2 knockdown impacts phosphatidylinositol 3-kinases/proto-oncogene protein akt (PI3K/AKT) signaling. | None |
| HIV-1 Nef and KSHV oncogene K1 synergistically promote angiogenesis by inducing cellular miR-718 to regulate the PTEN/AKT/mTOR signaling pathway. | None |
| Data indicate that microRNA miR-181b could activate HSCs, at least in part, via tensin homologs deleted on chromosome 10 (PTEN)/Akt proto-oncogene protein pathway. | None |
| Data indicate that proto-oncogene c-Akt (AKT1) is directly involved in miR-99a-mediated tumor suppression. | None |
| Data show that epiregulin-activated epidermal growth factor receptor (EGFR) and proto-oncogene protein AKT-mammalian target of rapamycin protein (mTOR) signalings are major pro-survival pathways. | None |
| Data show that the induction of resveratrol-dependent autophagy is mediated via the mechanistic target of Akt proto-oncogene protein/rapamycin complex 1 (mTORC1)/S6 kinase 1 (S6K1) signaling pathway. | None |
| Results indicate that proto-oncogene protein c-Akt inhibition contributed to cell death. | None |
| Data indicate that S-phase kinase-associated protein 2 (SKP2) cooperates with N-Ras and AKT proto-oncogenes to promote hepatocarcinogenesis in vivo. | None |
| The schweinfurthin class of compounds as a novel approach to modulate oncogenic mTOR/AKT signaling for cancer treatment. | None |
| The Akt1(Myr)/KRas(G12D) model holds promise for delineating the tumor biology and biomarkers critical for understanding their cooperation in cancer oncogenesis and future targeting in therapeutic strategies. | None |
| Data indicate that absence of proto-Oncogene protein Akt1 in vascular smooth muscle cell (VSMC) increases apoptosis in atherosclerotic plaques. | None |
| Data indicate that proto-oncogene protein Akt might play a vital role in the modulation of vascular smooth muscle cells (VSMCs) phenotype. | None |
| PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. | None |